BRCA1 and prostate carcinoma: Clinically, PARP inhibitors have improved outcomes compared with conventional therapy for both advanced and early-stage BRCA1/2-mutated breast cancer as well as ovarian and prostate cancers by extending disease-free and overall survival7.